SDC1 and plasma cell myeloma: This study reports a new immunofluorescence assay (i.e., CD138, BCMA, CD45, DAPI) for enrichment-free detection and characterization of BCMA-expressing cells in PC neoplasms, along with initial validation for utilizing this technology for tracking these cells across the myeloma progression spectrum.